SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-24-005145
Filing Date
2024-07-30
Accepted
2024-07-30 17:13:02
Documents
17
Period of Report
2024-07-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 31285
2 OPINION OF ARENTFOX SCHIFF LLP cns_ex0501.htm EX-5.1 13455
3 GRAPHIC header.jpg GRAPHIC 20835
4 GRAPHIC smlogo.jpg GRAPHIC 9131
5 GRAPHIC smartinyourworldlogo.jpg GRAPHIC 2993
  Complete submission text file 0001683168-24-005145.txt   269957

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20240730.xsd EX-101.SCH 3018
7 XBRL LABEL FILE cnsp-20240730_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE cnsp-20240730_pre.xml EX-101.PRE 22361
19 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3802
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 241158771
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)